Ublituximab(TG-1101)——一种新型糖工程化抗CD20抗体——联合依鲁替尼在复发和/或难治性慢性淋巴细胞白血病患者中安全且高度有效:2期试验结果
这项2期研究评估依鲁替尼联合Ublituximab治疗复发或难治性慢性淋巴细胞白血病(CLL)。45例入组患者中41例可评估疗效,6个月总缓解率(ORR)为88%;20例高危特征可评估患者ORR为95%,其中3例(15%)达到微小残留病阴性。中位起效时间8周。
要点
- 依鲁替尼420 mg每日一次联合Ublituximab方案在复发/难治CLL中6个月ORR达88%。
- 高危特征(17p或11q缺失或TP53突变)可评估患者20例,ORR为95%,3例(15%)MRD阴性。
- 中位起效时间8周,安全性与此前各药物经验一致,输注反应最常见。
核心结论
- Ublituximab联合依鲁替尼产生快速且高的缓解率。
- Ublituximab的长期临床获益将由正在进行的3期试验(NCT 02301156)确定。
研究设计与样本
- 2期研究,评估依鲁替尼与Ublituximab联合治疗复发或难治性慢性淋巴细胞白血病患者。
- 45例患者入组,其中41例可评估疗效。
- 依鲁替尼420 mg每日一次;Ublituximab在第1周期第1、8、15天给药,随后第2-6周期第1天给药。
- 第3和第6周期完成缓解评估;随后患者按标准治疗继续依鲁替尼单药治疗。
主要发现
- 联合治疗6个月总缓解率(ORR)为88%。
- 20例高危特征(17p或11q缺失或TP53突变)且可评估疗效的患者中,ORR为95%,3例(15%)达到微小残留病阴性。
- 中位起效时间为8周。
- 安全性与此前各药物经验一致,输注反应是最常见的不良事件。
局限性
- Ublituximab的长期临床获益将由正在进行的3期试验(NCT 02301156)确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel, glycoengineered anti-CD20 monoclonal antibody with single-agent activity in relapsed CLL. We report the results of a phase 2 study evaluating combination therapy with ibrutinib and ublituximab in patients with relapsed or refractory CLL. Patients received ibrutinib 420 mg once daily. Ublituximab was administered on days 1, 8 and 15 of cycle 1 followed by day 1 of cycles 2-6. Response assessments were completed at cycles 3 and 6; patients then continued on ibrutinib monotherapy per standard of care. Forty-one of 45 enrolled patients were evaluable for efficacy. Safety was consistent with prior experience for each drug, with infusion reactions the most prevalent adverse event. Combination therapy resulted in an overall response rate (ORR) of 88% at 6 months. In the 20 patients with high-risk features (17p or 11q deletions or TP53 mutation) and evaluable for efficacy, the ORR was 95%, with three patients (15%) achieving negative minimal residual disease. Median time to response was 8 weeks. Ublituximab in combination with ibrutinib resulted in rapid and high response rates. The long-term clinical benefit of ublituximab will be defined by an ongoing phase 3 trial (NCT 02301156).
引用
- Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol. 2016. PMID: 27982425. doi:10.1111/bjh.14447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。